February 8, 2018 / 9:39 AM / 5 months ago

BRIEF-GlaxoSmithKline Says ‍ViiV Healthcare Launches New Two-Drug HIV Study

Feb 8 (Reuters) - Glaxosmithkline Plc:

* ‍VIIV HEALTHCARE LAUNCHES EIGHTH PHASE III STUDY IN TWO-DRUG REGIMEN PROGRAMME FOR HIV-1 TREATMENT​

* ‍TANGO WILL SEEK TO ENROL APPROXIMATELY 550 ADULTS WITH HIV-1, FROM CLINICAL TRIAL SITES IN NORTH AMERICA, EUROPE, AUSTRALIA, AND JAPAN​

* EXPECTS ‍RESULTS OF TANGO IN 2019

* STUDY TO INVESTIGATE DOLUTEGRAVIR AND LAMIVUDINE IN PATIENTS WITH HIV WHO HAVE ACHIEVED VIRAL SUPPRESSION ON TENOFOVIR ALAFENAMIDE FUMARATE-BASED REGIMEN​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below